NEWS
Gorman-Rupp moves to NYSE
T
he Gorman-Rupp Co has transferred the listing of its common stock to the New York Stock Exchange (NYSE) from the NYSE MKT. The US pump company is continuing to trade under the ticker symbol GRC. “We believe listing on the NYSE, one of the world’s most recognized stock exchanges, will help the company reach investors and shareholders more efficiently and effectively,” said Jeffrey Gorman, president and CEO of Gorman-Rupp. Gorman-Rupp first listed on the American Stock Exchange in 1968. The company joined the NYSE Amex in 2009 following the NYSE’s acquisition of the American Stock Exchange. NYSE Amex changed its name to NYSE MKT in 2012. Incorporated in 1934, Gorman-Rupp manufactures pumps and pump systems for applications including water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, HVAC and military.
For further information, visit www.gormanrupp.com
Atlas Copco spin-off to be named Epiroc
A
tlas Copco has picked Epiroc as the name of the company that the group plans to dividend out next year (see Pump Industry Analyst, January 2017). Epiroc was chosen after an evaluation of almost 1000 names. Epi is a prefix meaning “on” or “at” in Latin and Greek, while Atlas Copco says Roc signals stability and durability and that rock is one of the most important materials that the company works with. “With Epiroc we have found a short, distinct and timeless name that is spot on for the mining and civil engineering business,” said Annika Berglund, Atlas Copco’s senior vice president Corporate Communications and Governmental Affairs. Earlier this year, Atlas Copco announced that it was preparing a proposal to split the group into two companies. Atlas Copco will concentrate on industrial customers, 16
Pump Industry Analyst
while Epiroc will focus on mining and civil engineering. Atlas Copco will propose the split at its 2018 Annual General Meeting. If the proposal is approved, the plan is to list Epiroc on the Nasdaq Stockholm stock exchange. For further information, visit www.atlascopco.com
Former Weir VP launches company to serve upstream oil & gas sector
C
hris Buckley, the former vice president of pressure pumping at Weir Oil & Gas, has established ST9 Gas + Oil, a Houston, Texas, USA-based company offering products, systems and services, including a range of pumps, to support drilling, well completion and production for upstream operations worldwide. “ST9 Gas + Oil was founded with the goal of disrupting the well service & completion industry,” said Buckley. “Well service companies are constantly challenged and frustrated by the system of timeworn practices and technologies, and so ST9 was born out of proven success in the gas & oil industry and with the purpose of winning the field by outperforming. We want to take down what is not working and replace it with products that have revolutionary function and values that retain.” ST9 Gas + Oil plans to roll out a number of new products this year, including well service pumps, well stimulation pumps, fluid ends, seats and valves, plungers, packing, high pressure flow control products and safety products. Before launching ST9 Gas + Oil, Buckley served as vice president of pressure pumping for Weir Oil & Gas, where he oversaw engineering, including new product development, quality, cost control, field service, testing and marketing. Prior to joining Weir in 2014, Buckley worked at Caterpillar Inc for almost eight years, in its Well Stimulation and Hydraulics business units.
Editorial Office: Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom Tel: +44 (0)1865 843695 Web: www.pumpindustryanalyst.com Editor: Roisin Reidy E-mail:
[email protected] Production Support Manager: Lin Lucas E-mail:
[email protected] Executive Publisher: Laney Priestley Subscription Information An annual subscription to Pump Industry Analyst includes 12 issues and online access for up to 5 users. Subscriptions run for 12 months, from the date payment is received. More information: More information: www.elsevier.com/journals/institutional/ pump-industry-analyst/1359-6128 Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, email: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 207 436 5931; fax: (+44) 207 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Digitally Produced by Mayfield Press (Oxford) LImited 12979
For further information, visit www.ST9GO.com
May 2017